Following an in-depth strategic review of its business Moulded GlassGerresheimer, German manufacturer of packaging systems and solutions, has announced its intention to sell its molded glass business. This future divestment is part of Gerresheimer's overall transformation into a specialized systems and solutions provider, focused exclusively on the pharmaceutical and biotechnology industries, with a targeted portfolio of primary packaging and drug delivery systems.
A Moulded Glass Powerhouse on a global scale
With the acquisition of Bormioli Pharma, Gerresheimer had built up a "strong" group. Moulded Glass Powerhouse "The company offers a diversified portfolio of products for the pharmaceutical, cosmetics and food industries.
The Moulded Glass resulting from the merger between Gerresheimer and Bormioli Pharma, comprises eight plants in Germany, Belgium, Italy, the United States and India. With around 3,700 employees, this entity generated pro forma sales of 735 million euros, with an adjusted EBITDA margin of around 20 % in fiscal 2024. This Moulded Glass Powerhouse boasts extensive know-how and global industrial capabilities for the production of Type I, II and III lenses, including decoration and customization services. Its diversified portfolio covers all types of glass packaging for the pharmaceutical, cosmetics and food industries: bottles, jars, containers and perfume bottles.
Over the past two years, Gerresheimer has invested around €100 million in modernizing and expanding its plant in Lohr am Main, Germany, installing a state-of-the-art, energy-efficient oxy-hybrid furnace.
Refocusing on the pharmaceutical and biotech industries
The planned divestment of the Moulded Glass business is a further step in Gerresheimer's transformation into a leading player exclusively dedicated to systems and solutions for the pharmaceutical and biotechnology industries. This transformation is accompanied by a growing share of specific solutions for biotherapies and other high value-added solutions. With the acquisition of Bormioli Pharma, Gerresheimer has expanded its portfolio to include new pharmaceutical primary packaging, closure systems, accessories and dosing devices, while paving the way for the integration of systems combined with high-end plastic solutions for the pharmaceutical and biotech industries.
"We see the best growth prospects for our new Moulded Glass Powerhouse outside the Gerresheimer Group, explains Dietmar Siemssen, CEO of Gerresheimer AG. As part of our strategic transformation, Gerresheimer will refocus on systems and solutions for the pharmaceutical and biotech industries."
Gerresheimer will provide further details on this divestment at its Capital Markets Day on October 15, 2025.
